Gonadotoxicity of cancer therapies in pediatric and reproductive-age males

Oncofertility Medical Practice: Clinical Issues and Implementation

Volumn , Issue , 2012, Pages 15-23

  Ginsberg, Jill P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904820525     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-9425-7_2     Document Type: Chapter

References (50)

1. Hewitt M, et al. Childhood cancer survivorship: improving care and quality of life. Washington, DC: National Academies Press; 2003.
2. Green DM, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:332-9.
3. Shalet SM, et al. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. J Endocrinol. 1989;120:161-5.
4. Meistrich ML. Male gonadal toxicity. Pediatr Blood Cancer. 2009;53:261-6.
5. Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol. 1999;33:2-8.
6. Morris ID. The testis: endocrine function. In: HiHer SG, Kitchener HC, Neilson JP, editors. Scientific essentials of reproductive medicine. London: Saunders; 1996.
7. Smith KD, Rodgriguez-Rigau LJ. Laboratory evaluation of testicular function. In: Degroot LJ, editor. Endocrinology. Philadelphia: Saunders; 1989.
8. Sherins RJ, Olweny CL, Ziegler JL. Gynaecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin’s disease. N Engl J Med. 1978;299:12-6.
9. Hobbie WL, et al. Fertility in males treated for Hodgkins disease with COPP/ABV hybrid. Pediatr Blood Cancer. 2005;44:193-6.
10. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am. 1998;27:927-43.
11. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin’s disease. Med Pediatr Oncol. 1996;27:74-8.
12. Papadakis V, et al. Gonadal function in young patients successfully treated for Hodgkin disease. Med Pediatr Oncol. 1999;32:366-72.
13. Ahmed SR, et al. Primary gonadal damage following treatment of brain tumors in childhood. J Pediatr. 1983;103:562-5.
14. da Cunha MF, Meistrich ML, Fuller LM. Recovery of spermatogenesis after treatment for Hodgkin’s disease: limiting dose of MOPP chemotherapy. J Clin Oncol. 1984;2:571-7.
15. Longhi A, et al. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol. 2003;25:292-6.
16. Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259:2123-5.
17. Thomson AB, et al. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. Lancet. 2002;360:361-7.
18. Aubier F, et al. Male gonadal function after chemotherapy for solid tumors in childhood. J Clin Oncol. 1989;7:304-9.
19. Kenney LB, et al. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001;91:613-21.
20. Colvin M. The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol. 1982;9:2-7.
21. Williams D, Crofton PM, Levitt G. Does ifosfamide affect gonadal function? Pediatr Blood Cancer. 2008;50:347-51.
22. Viviani S, et al. Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985;21:601-5.
23. Hassel JU, et al. Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin’s disease. Results in 25 patients of the DAL-HD-85 study. Klin Padiatr. 1991;203:268-72.
24. Charak BS, et al. Testicular dysfunction after cyclophosphamide-vincristine-procarbazine- prednisolone chemotherapy for advanced Hodgkin’s disease. A long-term follow-up study. Cancer. 1990;65:1903-6.
25. Radford JA, et al. Male fertility after VAPEC-B chemotherapy for Hodgkin’s disease and non- Hodgkin’s lymphoma. Br J Cancer. 1994;69:379-81.
26. Muller U, Stahel RA. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 1993;4:399-402.
27. Kulkarni SS, et al. Gonadal function following ABVD therapy for Hodgkin’s disease. Am J Clin Oncol. 1997;20:354-7.
28. Wallace WH, et al. Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia. Int J Androl. 1991;14:312-9.
29. Kreuser ED, et al. Reproductive and endocrine gonadal functions in adults following multidrug chemotherapy for acute lymphoblastic or undifferentiated leukemia. J Clin Oncol. 1988;6:588-95.
30. Meistrich M, et al. Recovery of sperm production after chemotherapy for osteosarcoma. Cancer. 1989;63:2115-23.
31. Lampe H, et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol. 1997;15:239-45.
32. Speiser B, Rubin P, Casarett G. Aspermia following lower truncal irradiation in Hodgkin’s disease. Cancer. 1973;32:692-8.
33. Hahn EW, Feingold SM, Nisce L. Aspermia and recovery of spermatogenesis in cancer patients following incidental gonadal irradiation during treatment: a progress report. Radiology. 1976;119:223-5.
34. Sandeman TF. The effects of x irradiation on male human fertility. Br J Radiol. 1966;39:901-7.
35. Ash P. The influence of radiation on fertility in man. Br J Radiol. 1980;53:271-8.
36. Kinsella TJ, et al. Long-term follow-up of testicular function following radiation therapy for early-stage Hodgkin’s disease. J Clin Oncol. 1989;7:718-24.
37. Shapiro E, et al. Effects of fractionated irradiation of endocrine aspects of testicular function. J Clin Oncol. 1985;3:1232-9.
38. Hahn EW, et al. Recovery from aspermia induced by low-dose radiation in seminoma patients. Cancer. 1982;50:337-40.
39. Sklar CA, et al. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group. J Clin Oncol. 1990;8:1981-7.
40. Petersen PM, et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol. 2002;20:1537-43.
41. Blatt J, et al. Leydig cell function in boys following treatment for testicular relapse of acute lymphoblastic leukemia. J Clin Oncol. 1985;3:1227-31.
42. Shalet SM, et al. Leydig cell damage after testicular irradiation for lymphoblastic leukaemia. Med Pediatr Oncol. 1985;13:65-8.
43. Leiper AD, Grant DB, Chessells JM. Gonadal function after testicular radiation for acute lymphoblastic leukaemia. Arch Dis Child. 1986;61:53-6.
44. Sarafoglou K, et al. Gonadal function after bone marrow transplantation for acute leukemia during childhood. J Pediatr. 1997;130:210-6.
45. Couto-Silva AC, et al. Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transpl. 2001;28:67-75.
46. Sanders JE, et al. Growth and development following marrow transplantation for leukemia. Blood. 1986;68:1129-35.
47. van Casteren NJ, et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer. 2009;52:108-12.
48. Redig AJ, et al. Incorporating fertility preservation into the care of young oncology patients. Cancer. 2011;117:4-10.
49. Woodruff TK. The Oncofertility Consortium-addressing fertility in young people with cancer. Nat Rev Clin Oncol. 2010;7:466-75.
50. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr. 2005;34:12-7.